Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma

Oncology Letters

Volumn 1, Issue 5, 2010, Pages 905-911

  Baba, Yasutaka ^a   Hayashi, Sadao ^a   Ueno, Kazuto ^a   Nakajo, Masayuki ^a   Ueno, Shinichi ^a   Kubo, Fumitake ^a   Baba, Yoshirou ^b   Hamanoue, Masahiro ^b   Hasegawa, Susumu ^a   Tsubouchi, Hirohito ^a   Komorizono, Yasuji ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Kagoshima Kouseiren Hospital   (Japan)

^c Nanpuh Hospital   (Japan)

Author keywords

Chemoembolization; Hepatic resection; Solitary hepatocellular carcinoma; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION;

EID: 77957555561     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000161     Document Type: Article

References (51)

1. Okuda K: Hepatocellular carcinoma. J Hepatol 32: 225-237, 2000.
2. Anonymous: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma: Groupe d' Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 332: 1256-1261, 1995.
3. Achenbach T, Seifert JK, Pitton MB, Schunk K and Junginger T: Chemoembolization for primary liver cancer. Eur J Surg Oncol 28: 37-41, 2002.
4. Dumortier J, Chapuis F, Borson O, et al: Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients. Dig Liver Dis 38: 125-133, 2006.
5. Mondazzi L, Bottelli R, Brambilla G, et al: Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 19: 1115-1123, 1994.
6. Lee HS, Kim KM, Yoon JH, et al: Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 10: 4459-4465, 2002.
7. The Cancer of the Liver Italian Program: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28: 751-755, 1998.
8. Sobin LH and Wittekind Ch (eds): International Union Against Cancer (UICC). Liver. TNM Classification of Malignant Tumours. 6th edition. John Wiley & Sons, Inc., New York, 2002.
9. Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 334: 693-699, 1996.
10. Brown DB, Gould JE, Gervais DA, et al: Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 18: 1469-1478, 2007.
11. Higashihara H and Okazaki M: Transcatheter arterial chemoem bolization of hepatocellular carcinoma: a Japanese experience. Hepatogastroenterology 28: 72-78, 2002.
12. Matsuo N, Uchida H, Nishimine K, et al: Segmental transcatheter hepatic artery chemoembolization with iodized oil for hepatocellular carcinoma: antitumor effect and influence on normal tissue. J Vasc Interv Radiol 4: 543-549, 1993.
13. Miyayama S, Matsui O, Yamashiro M, et al: Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 18: 365-376, 2007.
14. Nakamura H, Liu T, Hori S, et al: Response to transcatheter oily chemoembolization in hepatocellular carcinoma 3 cm or less: a study in 50 patients who underwent surgery. Hepatogastroenterology 3: 6-9, 1993.
15. Takayasu K, Muramatsu Y, Maeda T, et al: Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. Am J Roentgenol 176: 681-688, 2001.
16. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I and Nakajo M: Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 172: 1574-1581, 2000.
17. Ikai I, Arii S, Kojiro M, et al: Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101: 796-802, 2004.
18. Yamamoto J, Kosuge T, Saiura A, et al: Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria. Jpn J Clin Oncol 37: 287-295, 2007.
19. Sung Y, Choi D, Lim H, et al: Long-term results of percutaneous ethanol injection for the treatment of hepatocellular carcinoma in Korea. Korean J Radiol 7: 187-192, 2006.
20. Tateishi R, Shiina S, Teratani T, et al: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103: 1201-1209, 2005.
21. Imvrios G, Papanikolaou V, Vrochides D, et al: Liver transplantation outcomes in patients with cirrhosis and hepatocellular carcinoma: experience of a single center in a viral hepatitis endemic area. Transplant Proc 39: 1508-1510, 2007.
22. Bruix J, Llovet J, Castells A, et al: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27: 1578-1583, 1998.
23. Chen MS, Li JQ, Zhang YQ, et al: High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 8: 74-78, 2001.
24. Choi B, Kim H, Han J, et al: Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology 182: 709-713, 1992.
25. Eurvilaichit C: Outcome of transcatheter oily chemoem bolization in patients with hepatocellular carcinoma. Hepatogastroenterology 51: 20-24, 2004.
26. Hashimoto N, Kawai S, Mikuriya S, et al: Effects of transcatheter arterial chemoembolization with oral chemotherapy on hepatic neoplasms. Cancer Chemother Pharmacol 23: S21-S25, 1989.
27. Kamada K, Nakanishi T, Kitamoto M, et al: Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 12: 847-854, 2001.
28. Maeda S, Shibata J, Fujiyama S, et al: Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma. Hepatogastroenterology 50: 809-813, 2003.
29. Okusaka T, Okada S, Ueno H, et al: Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology 62: 228-233, 2002.
30. Ono Y, Yoshimasu T, Ashikaga R, et al: Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23: 564-568, 2000.
31. Shimamura Y, Gunven P, Takenaka Y, et al: Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE). Cancer 61: 238-242, 1987.
32. Stuart K, Stokes K, Jenkins R, Trey C and Clouse M: Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 72: 3202-3209, 1993.
33. Takayasu K, Arii S, Ikai I, et al: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469, 2006.
34. Takayasu K, Arii S, Matsuo N, et al: Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol 175: 699-704, 2000.
35. O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK and Fan ST: Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 90: 325-331, 2002.
36. Pelletier G, Ducreux M, Gay F, et al: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 29: 129-134, 1998.
37. Pelletier G, Roche A, Ink O, et al: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11: 181-184, 1990.
38. Llovet J, Real M, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 18: 1734-1739, 2002.
39. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
40. Takayasu K, Moriyama N, Muramatsu Y, et al: Hepatic arterial embolization for hepatocellular carcinoma. Comparison of CT scans and resected specimens. Radiology 150: 661-665, 1984.
41. Kudo M, Chung H, Haji S, et al: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40: 1396-1405, 2004.
42. Georgiades C, Liapi E, Frangakis C, et al: Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 17: 1619-1624, 2006.
43. Kudo M, Chung H and Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38: 207-215, 2003.
44. Leung T, Tang A, Zee B, et al: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94: 1760-1769, 2002.
45. Ueno S, Tanabe G, Nuruki K, et al: Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. J Hepatobiliary Pancreat Surg 9: 469-477, 2002.
46. Ueno S, Tanabe G, Sako K, et al: Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 34: 529-534, 2001.
47. Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918-928, 1985.
48. Pugh R, Murray-Lyon I, Dawson J, Pietroni M and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-669, 1973.
49. Majno PE, Sarasin FP, Mentha G and Hadengue A: Primary liver resection and salvage transplantation or primary liver transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 31: 899-906, 2000.
50. Belghiti J, Cortes A, Abdalla EK, et al: Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238: 885-892, 2003.
51. Roayaie S, Frischer JS, Emre SH, et al: Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235: 533-539, 2002